BTEC - Mirati: Not Looking Good In 2022 But Stronger Prospects In 2-3 Years June, 21 2022 05:10 PM Principal Healthcare Innovators Index ETF Mirati will probably not get accelerated approval for adagrasib in 2nd line NSCLC. This will delay their program for two years. However, much of their data is stronger than Amgen's lumakras. For further details see: Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years